The most useful sentence in this paper is the one the authors wrote against themselves. An estimated glomerular filtration rate is not measured; it is calculated from the creatinine in your blood, creatinine is a waste product of muscle, and semaglutide takes muscle mass off. Less muscle, less creatinine, a higher calculated eGFR — with the kidney doing exactly what it was doing before.
What was done
Adults with autosomal dominant polycystic kidney disease, an inherited condition with few treatment options, identified in a research network across 2000 to 2024. [1] Anyone on an SGLT2 inhibitor, tolvaptan or another GLP-1 was excluded. Of 45,613 patients, 323 had used semaglutide; 320 were matched one to one against non-users.
Excluding tolvaptan matters: it is the drug actually indicated for this disease, so this compares semaglutide against nothing in particular rather than against the standard of care.
What moved and what did not
Follow-up eGFR came out higher on semaglutide, 57.52 ± 28.19 against 50.93 ± 33.80 mL/min/1.73 m2, p = 0.013. Progression to stage 5 chronic kidney disease was lower, hazard ratio 0.447, 95% CI 0.230 to 0.872. Volume depletion and all-cause mortality were also lower.
End-stage kidney disease, acute kidney injury and urinary tract infection showed no significant difference.
Why a marker this common is so easy to move
Creatinine is convenient. It is on every routine blood panel, the equations are decades old, and nobody orders anything special. It is also a proxy, and it drifts with body composition whether or not the kidney changes.
That is the same structure as every other easily-moved surrogate on this site: the number closest to the mechanism moves most readily and establishes least. Cystatin C, a filtration marker that does not come from muscle, is the usual way to check this, and it is not in the published results here.
What a reader should do with it
Nothing, in terms of buying. Semaglutide is not a treatment for polycystic kidney disease and no seller on this roster offers it as one.
What is worth carrying is the check itself: when a drug that changes body composition improves a number derived from body composition, that is the first thing to ask about. It applies to eGFR, and it applies to every other result read off a calculated index in data collected outside a trial.